How to Get Repatha (Evolocumab) in Texas

What Repatha Is and Why Texas Patients Seek It

Repatha is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more receptors on the liver surface, pulling LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of diet and maximally tolerated statin therapy [1].

The FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 showed that adding evolocumab to statin therapy reduced the composite cardiovascular endpoint by 15% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) and cut LDL-C by a mean of 59% versus placebo at 48 weeks [2]. That magnitude of LDL-C reduction is not achievable with statins or ezetimibe alone in most patients with FH or refractory ASCVD.

Texas has a large population of patients with FH. The FH Foundation estimates that roughly 1 in 250 Americans has HeFH, translating to approximately 120,000 Texans who may qualify for evolocumab [3]. Yet access barriers, including prior authorization requirements and cost, mean that many eligible patients are not receiving the drug.

Who Qualifies for a Repatha Prescription in Texas

Most Texas payers and the FDA label agree on two primary eligibility categories. Adults with HeFH or HoFH who have not reached LDL-C goals on maximally tolerated statin therapy qualify. Adults with established ASCVD (prior MI, stroke, or peripheral arterial disease) who remain above LDL-C targets despite statins also qualify.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD who are at very high risk, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [4]. Texas prescribers use this language almost verbatim when writing medical necessity letters for prior authorization.

Statin intolerance is a second pathway. Patients who have documented myopathy, rhabdomyolysis, or intolerable myalgia on two or more statins at any dose may qualify for evolocumab even without prior statin maximization. Documentation in the medical record of at least two statin trials and the adverse effects experienced is the standard evidentiary requirement for insurers [5].

Labs required before prescribing typically include a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), a comprehensive metabolic panel (CMP) to assess hepatic and renal baseline, and, when statin intolerance is claimed, creatine kinase (CK). Results should be dated within 90 days of the prescription request to satisfy most Texas commercial plan PA criteria.

How Telehealth Prescribing Works in Texas

Texas allows telehealth prescribing of non-controlled prescription drugs, including biologics such as evolocumab. The Texas Medical Board codified this under Title 22, Part 9, Chapter 174 of the Texas Administrative Code, which requires that a valid patient-physician relationship be established before prescribing [6]. A synchronous video visit satisfies this requirement for most payers and the TMB.

Telehealth providers operating in Texas must hold an active Texas medical license or an out-of-state license recognized under the Interstate Medical Licensure Compact, to which Texas is a signatory. Nurse practitioners and physician assistants may also prescribe evolocumab in Texas under their collaborative practice agreements, provided the collaborating physician's scope permits it [7].

A typical telehealth encounter for evolocumab proceeds as follows. The patient completes an intake form documenting cardiovascular history, current medications, prior statin trials, and any adverse effects. The clinician reviews uploaded lab results, conducts a video visit to confirm eligibility, and, if criteria are met, sends the prescription electronically to a specialty pharmacy. The clinician then initiates the prior authorization paperwork, which may include a letter of medical necessity, lab evidence, and the relevant guideline citation.

HealthRX clinicians use a four-step eligibility checklist before initiating PA for evolocumab in Texas:

1. Confirm diagnosis (HeFH, HoFH, or established ASCVD) with ICD-10 code documentation.
2. Document LDL-C on maximally tolerated statin plus ezetimibe within 90 days (target not met: LDL-C at or above 70 mg/dL for ASCVD, or at or above 100 mg/dL for FH without ASCVD).
3. Record at least one statin trial at maximum tolerated dose for a minimum of 4 weeks, or document intolerance with two statin trials.
4. Confirm no active pregnancy (evolocumab is Pregnancy Category not assigned; Amgen advises avoiding use during pregnancy based on animal data) [1].

Navigating Prior Authorization in Texas

Prior authorization is the single most common barrier Texas patients face. A 2019 analysis published in JAMA Cardiology found that PA approval rates for PCSK9 inhibitors hovered near 55% on initial submission across commercial US plans, with denial rates highest when LDL-C documentation was incomplete [8]. Getting it right on the first submission saves weeks.

The documentation package for a Texas commercial plan PA typically includes: the completed insurer-specific PA form, a letter of medical necessity on provider letterhead citing the ACC/AHA Class I indication, a copy of the most recent fasting lipid panel, a medication history showing current statin and ezetimibe use (or documented intolerance), and the patient's relevant ICD-10 diagnosis codes (E78.01 for HeFH, E78.02 for HoFH, I25.10 for chronic ischemic heart disease, or similar) [9].

Texas Medicaid (STAR/CHIP/STAR+PLUS) does not cover evolocumab for FH or ASCVD under its current preferred drug list. The state formulary restricts PCSK9 inhibitor coverage to patients with type 2 diabetes in specific managed care organization plans. Patients enrolled in Texas Medicaid who have FH or ASCVD will need to explore manufacturer assistance programs rather than Medicaid coverage [10].

Amgen's Repatha Copay Card reduces out-of-pocket cost to as low as zero dollars per month for commercially insured patients. Patients without insurance may apply to Amgen's FIRST STEP program, which provides Repatha free of charge to qualifying low-income patients [11].

Appeals are common. If an initial PA is denied, Texas law (Texas Insurance Code Chapter 4201) gives patients the right to an independent review organization (IRO) appeal within 30 days of denial. A 2021 study in Circulation: Cardiovascular Quality and Outcomes found that nearly 40% of initially denied PCSK9 inhibitor PAs were ultimately approved after appeal, underscoring the value of a well-documented medical necessity argument [12].

Finding a Texas Prescriber: In-Person vs. Online

Any Texas-licensed MD, DO, NP (with prescriptive authority and a collaborative agreement), or PA (under physician supervision) may prescribe evolocumab [7]. Patients seeking in-person care typically see a cardiologist, a lipidologist, or a primary care physician who manages cardiovascular risk. The National Lipid Association maintains a provider directory at lipid.org where patients can search by ZIP code for Texas lipidologists.

Online options have expanded since 2020. Multiple telehealth platforms now hold Texas provider licenses and can handle the full workflow from intake to PA submission to specialty pharmacy coordination within a single platform visit. The Texas Medical Board requires that the prescriber document that a proper physical or electronic examination was conducted and that the prescription is appropriate for the patient's condition [6].

A cardiologist consultation carries weight in PA submissions. Several Texas Blue Cross Blue Shield and Aetna plans list cardiologist or lipidologist involvement as a PA preference, though not a hard requirement, for PCSK9 inhibitor approvals. When a telehealth platform employs board-certified cardiologists or internists with lipid expertise, the PA approval rate is similar to in-person specialty care.

Texas Pharmacies and Specialty Dispensing

Evolocumab requires cold-chain storage (refrigerated, 36 to 46 degrees Fahrenheit) and is dispensed almost exclusively through specialty pharmacies. The three largest specialty pharmacy networks serving Texas patients are CVS Specialty, Walgreens Specialty, and Accredo (an Express Scripts company). All three are licensed in Texas and can ship to any Texas address via insulated overnight packaging [13].

503A compounding pharmacies in Texas operate under Texas State Board of Pharmacy oversight and may compound patient-specific preparations, but evolocumab is a biologic produced through recombinant DNA technology in mammalian cell culture. It cannot be compounded by a 503A or 503B pharmacy under current FDA guidance, which prohibits compounding of approved biologics when a commercially available product exists [14]. Any offer of "compounded evolocumab" from a Texas pharmacy is not legally or scientifically valid.

Once a PA is approved and the specialty pharmacy receives the prescription and insurance information, first delivery to a Texas address typically takes 3 to 7 business days. Including the time required for the PA review itself (7 to 14 days for standard review, 72 hours for urgent review under Texas Insurance Code), most patients receive their first injection within 2 to 6 weeks of the initial telehealth or clinic visit.

Patients who relocate to Texas with an existing Repatha prescription from another state may transfer the prescription to a Texas-licensed specialty pharmacy. The prescribing provider does not need to be relicensed in Texas if the original prescription was written lawfully. However, if a new PA is required by the Texas-based insurance plan, the transferring prescriber or a new Texas provider will need to submit documentation meeting Texas plan requirements.

What to Expect After Starting Repatha

Evolocumab begins reducing LDL-C within days of the first injection. By week 4, mean LDL-C reductions of approximately 55 to 65% are typically observed relative to baseline [2]. The 140 mg every-2-weeks autoinjector and the 420 mg once-monthly SureClick autoinjector produce equivalent LDL-C lowering; the choice depends on patient preference for injection frequency [1].

Injection site reactions occurred in 3.2% of FOURIER participants versus 3.0% in the placebo group, indicating the drug is generally well tolerated locally [2]. Nasopharyngitis and upper respiratory infections were the most common adverse events overall. Neurocognitive events were evaluated in the EBBINGHAUS substudy (N=1,974), which found no significant difference in cognitive scores between evolocumab and placebo over a median follow-up of 19 months [15].

Follow-up lipid panels are typically ordered at 4 to 8 weeks after the first dose to confirm therapeutic response and support PA renewals. Most Texas commercial plans require annual PA reauthorization, and a follow-up lipid panel showing LDL-C response is the strongest supporting document for renewal [5].

Patients should store prefilled autoinjectors in the refrigerator and allow the pen to reach room temperature for 30 minutes before injection to reduce injection site discomfort. Injections are given in the abdomen, upper arm, or thigh, rotating sites with each dose.

LDL-C Targets and Monitoring After Starting Treatment

The ACC/AHA 2022 guideline recommends an LDL-C target of <70 mg/dL for very high-risk ASCVD patients and <100 mg/dL for high-risk FH patients without established ASCVD [4]. The IMPROVE-IT trial (N=18,144) demonstrated that achieving lower LDL-C levels with ezetimibe added to simvastatin reduced cardiovascular events incrementally, establishing the principle that lower is better for LDL-C [16]. Evolocumab carries this strategy substantially further.

A 2020 meta-analysis in The Lancet (N=75,299 participants across 4 PCSK9 inhibitor trials) found a 19% relative risk reduction in major adverse cardiovascular events per 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C, consistent with the statin literature's on-treatment LDL-C benefit curve [17]. This evidence base supports aggressive LDL-C lowering in high-risk Texas patients who remain above guideline targets on statins alone.

Monitoring after achieving target LDL-C includes annual fasting lipid panels, annual CMP to check hepatic function, and periodic evaluation of injection technique and adherence. No dose adjustment is required for renal impairment. Dose adjustment for hepatic impairment is not formally established; use in severe hepatic impairment should be discussed with a specialist [1].